New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Psyence Biomedical Ltd.

PBM

Healthcare Biotechnology

2.97 0.11 +3.85%

After hours trading: 3.01, up 1.35%, last trade Fri 4:09pm Eastern.

Market cap
$10.9M
P/E
0.1×
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
—
Net debt / EBITDA
1.2×
Payout ratio
—

Ratios over time FY23 to FY26

Returns on capital

ROIC was −41.2% in FY26, against a low of −415.6% in FY25. ROE, at −58.6%, is far above it because equity is small against the capital the business uses.

ROEROIC
FY23FY24FY25FY26
ROE−54.7%149.5%−47.6%−58.6%
ROIC0.0%0.0%−415.6%−41.2%

Debt

Net debt is 1.20× a year’s EBITDA. Debt is 0.00× equity.

Debt / equityNet debt / EBITDA
FY20FY21FY23FY24FY25FY26
Debt / equity0.0×0.0×0.0×0.0×0.0×0.0×
Net debt / EBITDA1.9×0.1×0.3×0.3×1.7×1.2×
Dec '17 Jan '21 Jan '22 Dec '23 Mar '24 Mar '25 Mar '26
Current Ratio
— 14.17 0.08 0.09 0.09 11.04 14.62
Net Debt/EBITDA
— 1.94 0.10 0.28 0.28 1.69 1.20
Debt/Equity
— 0.00 0.00 0.00 0.00 0.00 0.00
ROE
— — 3.33% (54.66%) 149.52% (47.61%) (58.62%)
ROA
— 6.42% 3.11% (39.34%) (4,518.56%) 23.95% (55.75%)
ROIC
— — — 0.00% 0.00% (415.57%) (41.24%)
Return on Tangible Assets
— 909.94% (61.34%) 466.25% 466.25% 16.93% (81.67%)
Free Cash Flow per Share
— (0.03) (0.02) — (1,735.94) (121.17) (14.74)
Book value per Share
— 7.24 7.49 (1.32) (6,454.41) 217.54 30.68
Free Cash Flow
— (0.84) (0.52) — (2.95) (3.74) (8.14)
Other line items

Show all line items

Columns are period end dates